- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1732
|
In vitro |
DMSO
: 64 mg/mL
(199.97 mM)
Ethanol : 64 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 320.04 | Formula | C14H10Cl4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 53-19-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NCI-C04933 | Smiles | C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl | ||
| Targets/IC50/Ki |
Sterol-O-Acyl Transferase 1
|
|---|---|
| In vitro |
Mitotane inhibits both TSH expression and secretion, blocks TSH response to TRH, and reduces cell viability, inducing apoptosis at concentrations in the therapeutic window in the mouse TalphaT1 cell line. This compound does not interfere with thyroid hormone laboratory tests but directly reduces both secretory activity and cell viability on pituitary TSH-secreting mouse cells. It induces adrenal cortex necrosis, mitochondrial membrane impairment, and irreversible binding to CYP proteins. This chemical (10-40μM) inhibits basal and cAMP-induced cortisol secretion but does not cause cell death. It exhibits an inhibitory effect on the basal expression of StAR and P450scc protein. This agent (40 μM) significantly diminishes StAR, CYP11A1 and CYP21 mRNA expression. This compound (40μM) almost completely neutralizes this positive effect and returned 8-Br-cAMP-induced StAR, CYP11A1, CYP17 and CYP21 mRNA to control levels. Its combination with gemcitabine shows antagonistic effects and interfered with the gemcitabine-mediated inhibition of the S phase of the cell cycle in H295R cells.
|
| In vivo |
Mitotane (60 mg/kg) significantly decreases adrenal mitochondrial and microsomal "P-450" and microsomal protein content 34%, 55%, and 35% respectively in rats, within 3 hours.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06279442 | Not yet recruiting | Carcinoma Adrenal|Carcinoma Adrenocortical Recurrent |
Latin American Cooperative Oncology Group |
June 2024 | -- |
| NCT05344027 | Completed | Adrenocortical Carcinoma |
King''s College Hospital NHS Trust |
April 11 2022 | -- |
| NCT02057237 | Completed | Prostate Cancer |
University Health Network Toronto |
September 2013 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.